INT3545

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1976
Last Reported 2010
Negated 1
Speculated 2
Reported most in Body
Documents 27
Total Number 29
Disease Relevance 11.97
Pain Relevance 14.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Mtx1)
Anatomy Link Frequency
Plasma 1
pseudotumor 1
SRBC 1
Mtx1 (Mus musculus)
Pain Link Frequency Relevance Heat
methotrexate 1122 100.00 Very High Very High Very High
Etanercept 591 100.00 Very High Very High Very High
Infliximab 497 100.00 Very High Very High Very High
abatacept 153 100.00 Very High Very High Very High
corticosteroid 7 99.84 Very High Very High Very High
rheumatoid arthritis 343 99.66 Very High Very High Very High
Arthritis 307 98.88 Very High Very High Very High
Morphine 9 98.48 Very High Very High Very High
dysesthesia 3 97.52 Very High Very High Very High
Leflunomide 12 96.20 Very High Very High Very High
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 439 100.00 Very High Very High Very High
Disease 339 99.78 Very High Very High Very High
Cancer 30 99.52 Very High Very High Very High
Juvenile Chronic Polyarthritis 207 98.88 Very High Very High Very High
Hypersensitivity 11 98.70 Very High Very High Very High
Toxicity 53 98.36 Very High Very High Very High
Paraplegia 1 98.30 Very High Very High Very High
Congenital Anomalies 15 98.16 Very High Very High Very High
Dysesthesia 7 96.60 Very High Very High Very High
Poisoning 217 90.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Dupuis et al. [27] administered MTX to 14 patients (ages: 2.8–15.1 years, including 10 females) for 3 weeks using three dosing methods (administration after a meal, administration after overnight hunger, and intravenous administration).
Positive_regulation (administered) of MTX associated with methotrexate
1) Confidence 0.42 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 0.07 Pain Relevance 0.42
Plasma levels of MTX administered intravenously to mice are elevated by the concomitant administration of morphine, which reduces renal elimination of MTX.
Positive_regulation (elevated) of MTX in Plasma associated with methotrexate and morphine
2) Confidence 0.41 Published 2004 Journal Clin. Exp. Pharmacol. Physiol. Section Abstract Doc Link 15053825 Disease Relevance 0 Pain Relevance 1.12
In the terminal stage the patient developed paraplegia which, partly on the basis of neuropathological findings, was ascribed to the large accumulated dose of MTX.
Positive_regulation (accumulated) of MTX associated with paraplegia
3) Confidence 0.40 Published 1976 Journal Clin Neurol Neurosurg Section Abstract Doc Link 800969 Disease Relevance 0.68 Pain Relevance 0.13
Evaluation of the effects of MTX dose increase [18]
Positive_regulation (increase) of MTX associated with methotrexate
4) Confidence 0.39 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 1.05 Pain Relevance 0.97
It is also noteworthy that ASA significantly increased the exposure of the subject to 7-OH-MTX and, to a lesser extent, so did sulindac.
Positive_regulation (increased) of MTX associated with methotrexate
5) Confidence 0.39 Published 1990 Journal J Pharm Sci Section Abstract Doc Link 2273459 Disease Relevance 0.22 Pain Relevance 1.00
Of the immunosuppressants, CsA reduced all the DH reactions while Aza mainly reduced the reaction to SRBC; Cy and Mtx were mainly active on SBRC and MBSA inflammations.
Positive_regulation (active) of Mtx in SRBC associated with hypersensitivity
6) Confidence 0.39 Published 1990 Journal Arzneimittelforschung Section Abstract Doc Link 2291750 Disease Relevance 1.26 Pain Relevance 0.43
Simultaneous administration of ketoprofen was associated with prolonged and striking enhancement of serum MTX levels.
Positive_regulation (enhancement) of serum MTX associated with methotrexate
7) Confidence 0.33 Published 1986 Journal Lancet Section Abstract Doc Link 2868265 Disease Relevance 0.29 Pain Relevance 0.48
In addition, the positive impact of concomitant MTX was also associated primarily with fewer dropouts because of AEs.
Positive_regulation (impact) of MTX associated with methotrexate
8) Confidence 0.26 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1794519 Disease Relevance 0 Pain Relevance 0.69
Nevertheless, our data suggest that patients who tolerate MTX well also are likely to tolerate TNF-blocking agents.
Positive_regulation (tolerate) of MTX associated with methotrexate
9) Confidence 0.26 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1794519 Disease Relevance 0 Pain Relevance 0.65
Decreased 7-OH-MTX formation suggests folic acid inhibition of AO and a better clinical response, while increased 7-OH-MTX formation may interfere with MTX polyglutamylation and binding to enzymes and, therefore, may increase MTX excretion and decrease MTX retention and efficacy in vivo.


Spec (may) Positive_regulation (increase) of MTX
10) Confidence 0.25 Published 2009 Journal Arthritis Rheum. Section Body Doc Link 19644884 Disease Relevance 0 Pain Relevance 0
Anderson et al7 identified disease duration as the strongest predictor of treatment response in a meta-analysis of 1435 patients, with patients with longer disease duration at the start of treatment being less likely to respond to MTX.
Spec (likely) Positive_regulation (respond) of MTX associated with disease and methotrexate
11) Confidence 0.23 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2596302 Disease Relevance 0.86 Pain Relevance 0.25
Interestingly, the strongest factor demonstrated was the association between being positive for the HLA DRB1 SE and stopping MTX for inefficacy.
Positive_regulation (stopping) of MTX associated with methotrexate
12) Confidence 0.23 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2596302 Disease Relevance 0.44 Pain Relevance 0.48
These results reflect an earlier termination of MTX in biopsied patients because of hepatic toxicity.
Positive_regulation (termination) of MTX associated with toxicity and methotrexate
13) Confidence 0.21 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2945037 Disease Relevance 1.41 Pain Relevance 0.45
Early MTX in usual clinical care of RA increased from <5% in 1980 to >90% in 2004.
Positive_regulation (increased) of MTX associated with rheumatoid arthritis
14) Confidence 0.18 Published 2008 Journal Rheumatology (Oxford, England) Section Abstract Doc Link PMC2544432 Disease Relevance 0.17 Pain Relevance 0.07
Around 40% had previously received MTX (but patients previously treated with MTX had neither discontinued it owing to toxicity nor been treated with MTX within 6 months of enrolment).
Positive_regulation (received) of MTX associated with toxicity and methotrexate
15) Confidence 0.14 Published 2008 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2377247 Disease Relevance 0.46 Pain Relevance 0.95
drugs depending on prior exposure and response to MTX
Positive_regulation (response) of MTX associated with methotrexate
16) Confidence 0.14 Published 2008 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2377247 Disease Relevance 0 Pain Relevance 0.22
It has been suggested that patients with rheumatoid arthritis who are able to tolerate MTX represent a subset with better prognosis than those patients who cannot take MTX.
Positive_regulation (tolerate) of MTX associated with rheumatoid arthritis and methotrexate
17) Confidence 0.14 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC333416 Disease Relevance 0.54 Pain Relevance 0.56
One important difference between the two treatment groups, which cannot be eliminated, is the fact itself that the monotherapy group did not receive MTX.
Neg (not) Positive_regulation (receive) of MTX associated with methotrexate
18) Confidence 0.14 Published 2003 Journal Arthritis Res Ther Section Body Doc Link PMC333416 Disease Relevance 0.23 Pain Relevance 0.27
The positive results of MTX-IFX need to be put into perspective.
Positive_regulation (results) of MTX associated with infliximab
19) Confidence 0.09 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376089 Disease Relevance 0.60 Pain Relevance 0.57
The recent COMET study (Emery et al 2007) was designed to evaluate the DAS28 remission rate obtained after 1 and 2 years of therapy in 528 patients with early RA (<2 years disease duration) receiving etanercept plus MTX or MTX alone.
Positive_regulation (receiving) of MTX associated with rheumatoid arthritis, disease, methotrexate and etanercept
20) Confidence 0.08 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721350 Disease Relevance 0.39 Pain Relevance 0.98

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox